表紙
市場調査レポート

2017年までの睡眠障害市場:ジェネリック医薬品の登場とパイプラインの弱体化が市場にマイナスの影響

Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market

発行 GBI Research 商品コード 189222
出版日 ページ情報 英文 141 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
2017年までの睡眠障害市場:ジェネリック医薬品の登場とパイプラインの弱体化が市場にマイナスの影響 Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market
出版日: 2011年04月11日 ページ情報: 英文 141 Pages
概要

睡眠障害市場は急速に成長してきました。不眠症は、作業場での慢性的障害の主な要因と考えられてきました。2010年、睡眠障害市場は35億米ドルとなりましたが、2017年には34億米ドルに減少する見込みです。その主な原因が不眠症市場です。不眠症治療薬市場はこれまで急速に拡大してきましたが、2011〜2017年は3.8%減となる見込みです。競争が激しく、新規参入に対する障壁があるためです。こうした状況が、下肢静止不能症候群、ナルコレプシー、睡眠時無呼吸症候群などの分野にも波及しています。

当レポートでは、睡眠障害市場について分析し、市場の概要と地域別、治療分野別動向、新製品開発パイプライン、競合動向、業界内でのM&A動向などをまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 市場概要

  • イントロダクション
  • 睡眠障害治療薬市場の収益予測
    • 収益
    • 年間治療費
    • 治療使用形態

第4章 地域別環境

  • 地域別収益分析
    • 米国
    • 欧州5カ国
    • 日本

第5章 治療分野

  • 不眠症
  • 下肢静止不能症候群
  • ナルコレプシー
  • 睡眠時無呼吸症候群

第6章 パイプライン分析

  • イントロダクション
  • 研究開発パイプライン:睡眠障害
  • 不眠症
  • 下肢静止不能症候群
  • ナルコレプシー
  • 睡眠時無呼吸症候群

第7章 競合環境

  • 市場シェア分析
  • 競合プロファイリング

第8章 M&A環境

  • 睡眠障害市場
  • 合併・買収
  • ライセンシング契約
  • 共同開発

第9章 付録

目次
Product Code: GBIHC095MR

Summary

GBI Research, the leading business intelligence provider, has released its latest research “Sleep Disorders Market to 2017- Generics Substitution Coupled with a Weak Pipeline Will Negatively Impact the Market”, which provides insights into sleep disorders therapeutics sales and price forecasts until 2017. The report also examines the global sleep disorders treatment usage patterns. In addition, the geographical distribution of sleep disorders therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the sleep disorders R&D pipeline. The report provides an in-depth analysis of the top four sleep disorders therapeutic indications, which are insomnia, restless leg syndrome, narcolepsy and sleep apnea. Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also explores the competitive landscape including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving sleep disorders treatments is also presented.

Scope

The report covers -
•  Data and analysis on the sleep disorders therapeutics market in the leading geographies of the world - the US, the UK, Germany, France, Italy, Spain, and Japan.
•  Annualized market data for the sleep disorders therapeutics market from 2002 to 2010, with forecasts to 2017.
•  Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
•  Key drivers and restraints that have had a significant impact on the market.
•  The competitive landscape of the global sleep disorders therapeutics market including top companies benchmarking. The key companies studied in this report are Sanofi-aventis, King pharmaceuticals, questcor pharmaceuticals, Novartis, GlaxoSmithKline, plc, Pfizer and Boehringer Ingelheim
•  Key M&A activities and Licensing Agreements that took place in 2008 and 2010 in the sleep disorders therapeutics market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
•  Build effective strategies to launch their pipeline products by identifying potential geographies.
•  Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
•  Develop key strategic initiatives by studying the key strategies of top competitors.
•  Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
•  Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Executive Summary

GBI Research, the leading business intelligence provider has released its latest research “Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market”, which essentially provides insights on sleep disorders therapeutics sales and price forecasts until 2017. The report also examines the global sleep disorders treatment usage patterns. In addition, the geographical distribution of sleep disorders treatments across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the sleep disorders Research and Development (R&D) pipeline and the potential future blockbusters up to 2017. The report provides an in-depth analysis of the top four sleep disorders therapeutic indications, which are insomnia, restless leg syndrome, narcolepsy and sleep apnea. Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also explores the competitive landscape including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving sleep disorders treatment is also presented.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

High Growth Rate and Increasing Necessity for CNS Drugs has Made the Sleep Disorder Market Attractive

The sleep disorders market has been a fast growing market, with insomnia considered to be the prime factor for chronic disability in the workforce. In 2010, the Sleep Disorders Market was worth $3.5 billion, which is forecast to decrease to $3.4 billion by 2017, with a rate of -0.4% between 2010 and 2017. This is mainly affected by insomnia, which is a leading indication among all types of sleep disorders.

The insomnia therapeutics market has been growing at a fast pace over the past few years, but is expected to decline with a rate of -3.8% from 2011 to 2017 due to high competition in the market, which will be a barrier for prospective entrants. This competition can be transmitted over other indications in the market such as restless leg syndrome, narcolepsy and sleep apnea. This can be carried out by practicing patient awareness about the diseases and types of treatments, while the other method is by increasing diagnosis.

Sleep Disorders Market, Revenue Forecasts ($bn), 2002-2017

Source: GBI Research

The Insomnia Market will Decline Moderately Due to Patent Expirations

The insomnia therapeutics market was a growing market during 2002-2009, and the growth was dominated by the US market. The growth rate is likely to decline from 2011 onwards due to the impact of patent expiry of key drugs. However, new branded drugs will minimize the impact of generic erosion to some extent. This impact will be seen due to patent expiries in the insomnia market, as it accounts for approximately 79% share of the global market. The global insomnia therapeutics market is expected to decline at a CAGR of -3.8%, from $2.8 billion in 2010 to $2.1 billion in 2017. The major causes for decline in the market are patent expiries of major drugs and weak profile of current pipeline molecules. The global insomnia therapeutics market in 2010 was worth $2.8 billion, which was primarily formed of three brands, namely Lunesta (eszopiclone), Paxil (paroxetine) and Ambien (zolpidem). The cost of therapy for branded products is in the range of $750 to $1,002 for duration of six months, as compared to those of generics which is between $10 and $20 for the same duration. The most popular product for insomnia was Ambien (including generics and (Controlled Releases [CRs]), which demonstrates the large extent to which older generation products have been successful in terms of satisfying market demand. Ambien was approved for short term treatment of insomnia, while Ambien CR was approved for prescription for up to six months in 1991. The Average Selling Price (ASP) of products in the market is in the
Restless Leg Syndrome, Narcolepsy and Sleep Apnea are Dominated by Late-Stage Pipeline Molecules that will Boost the Competition

The restless leg syndrome, narcolepsy and sleep apnea pipeline portfolios have 12, five and 11 molecules across the different developmental stages, respectively. The number of programs in the regulatory filing, Phase III and Phase II stages of development accounted for approximately 79% of the total number of pipeline programs. This indicates that the imminent launch of these drugs could increase the sleep disorder market value.

The restless leg syndrome market has a strong pipeline that will support the growth of this market, thereby attracting many pharmaceutical and biotechnological companies. Major pharmaceutical companies such as UCB Group, GlaxoSmithKline plc, axxonis Pharma AG, Ligand Pharmaceuticals Incorporated, National Institute of Neurological Disorders and Stroke, Kyowa Hakko Kirin Co., Ltd., Jazz Pharmaceuticals, Inc., Otsuka Holdings Co., Ltd., Omeros Corporation and Manhattan Pharmaceuticals, Inc., are actively developing molecules for restless leg syndrome.

The entry of pipeline molecules will boost the sleep disorder therapeutics market, thereby bringing about further rises in the sleep disorder therapeutics market in the coming years. Rapid entry of new players and highly active pipelines will intensify competition.

Sleep Disorder Therapeutics Market, R&D Pipeline by Phase (%), 2004-2010

Source: GBI Research’s Internal Database, Company Websites, Clinicaltrials.gov

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Sleep Disorders Market: Introduction

  • 2.1. GBI Research Report Guidance

3. Sleep Disorders Market to 2017: Market Overview

  • 3.1. Introduction
  • 3.2. Revenue Forecasts for the Sleep Disorder Therapeutics Market
    • 3.2.1. Revenue
    • 3.2.2. Annual Cost of Treatment (ACT)
    • 3.2.3. Treatment Usage Patterns

4. Sleep Disorders Market to 2017: Geographical Landscape

  • 4.1. Revenue Analysis by Geography
  • 4.2. The US
    • 4.2.1. Revenue
    • 4.2.2. Annual Cost of Treatment
    • 4.2.3. Treatment Usage Patterns
  • 4.3. Top Five Countries of Europe
    • 4.3.1. Revenue
    • 4.3.2. Annual Cost of Treatment
    • 4.3.3. Treatment Usage Patterns
  • 4.4. Japan
    • 4.4.1. Revenue
    • 4.4.2. Annual Cost of Treatment
    • 4.4.3. Treatment Usage Patterns

5. Sleep Disorders Market: Therapeutic Landscape

  • 5.1. Insomnia Therapeutics Market
    • 5.1.1. Introduction
    • 5.1.2. Revenue
    • 5.1.3. Annual Cost of Treatment
    • 5.1.4. Treatment Usage Patterns
    • 5.1.5. Drivers and Barriers for the Insomnia Therapeutics Market
  • 5.2. Restless Leg Syndrome Therapeutics Market
    • 5.2.1. Introduction
    • 5.2.2. Revenue
    • 5.2.3. Annual Cost of Treatment
    • 5.2.4. Treatment Usage Patterns
    • 5.2.5. Drivers and Barriers for the Restless Leg Syndrome Therapeutics Market
  • 5.3. Narcolepsy Therapeutics Market
    • 5.3.1. Introduction
    • 5.3.2. Revenue
    • 5.3.3. Annual Cost of Treatment
    • 5.3.4. Treatment Usage Patterns
    • 5.3.5. Drivers and Barriers for the Narcolepsy Therapeutics Market
  • 5.4. Sleep Apnea Therapeutics Market
    • 5.4.1. Introduction
    • 5.4.2. Revenue
    • 5.4.3. Annual Cost of Treatment
    • 5.4.4. Treatment Usage Patterns
    • 5.4.5. Drivers and Barriers for the Sleep Apnea Therapeutics Market

6. Sleep Disorders Market to 2017: Pipeline Analysis

  • 6.1. Introduction
  • 6.2. Research and Development Pipeline - Sleep Disorders
  • 6.3. Insomnia - Pipeline Analysis
    • 6.3.1. Introduction
    • 6.3.2. Insomnia Therapeutics Market - Pipeline Assessment by Clinical Phase of Development
    • 6.3.3. Filed Molecules
    • 6.3.4. Phase III
    • 6.3.5. Phase II
    • 6.3.6. Phase I
    • 6.3.7. Preclinical Phase
    • 6.3.8. Discovery Phase
  • 6.4. Restless Leg Syndrome Therapeutics Market: Pipeline Analysis
    • 6.4.1. Introduction
    • 6.4.2. Narcolepsy Therapeutics Market - Pipeline Assessment by Clinical Phase of Development
  • 6.5. Narcolepsy Therapeutics Market - Pipeline Analysis
    • 6.5.1. Introduction
    • 6.5.2. Narcolepsy Therapeutics Market - Pipeline Assessment by Clinical Phase of Development
  • 6.6. Sleep Apnea Therapeutics Market - Pipeline Analysis
    • 6.6.1. Introduction
    • 6.6.2. Sleep Apnea Therapeutics Market - Pipeline Assessment by Clinical Phase of Development

7. Sleep Disorder Market to 2016: Competitive Landscape

  • 7.1. Overview
  • 7.2. Competitive Profiling
    • 7.2.1. Sanofi-Aventis
    • 7.2.2. King Pharmaceuticals, Inc.
    • 7.2.3. Questcor Pharmaceuticals, Inc.
    • 7.2.4. Novartis
    • 7.2.5. GlaxoSmithKline plc
    • 7.2.6. Pfizer
    • 7.2.7. Boehringer Ingelheim
    • 7.2.8. Cephalon Pharmaceuticals
    • 7.2.9. Schwarz Pharma
    • 7.2.10. Mylan Pharma

8. Sleep Disorders Market to 2017: M&A Landscape

  • 8.1. Sleep Disorders Market
    • 8.1.1. Overview: Deals by Type
    • 8.1.2. Deals by Year
  • 8.2. Mergers and Acquisitions
    • 8.2.1. Overview
    • 8.2.2. Meda Acquires Commercialization Rights of Sublinox and OX-NLA from Orexo
    • 8.2.3. Eli Lilly Acquires Hypnion
    • 8.2.4. Endo Pharmaceuticals Completes Acquisition of Penwest Pharmaceutical
    • 8.2.5. Sciele Pharma Acquires Alliant Pharmaceuticals
    • 8.2.6. Jazz Pharmaceuticals Acquires Orphan Medical
    • 8.2.7. Paul Royalty Acquires US Royalty Rights of Estorra from Aventis
  • 8.3. Licensing Agreements
    • 8.3.1. GlaxoSmithKline (GSK) and Actelion Pharmaceuticals
    • 8.3.2. Purdue Pharma Enters into License Agreement with Transcept Pharmaceuticals
    • 8.3.3. Neurocrine Biosciences Enters into Licensing Agreement with Dainippon Sumitomo Pharma
    • 8.3.4. Eli Lilly Enters into Licensing Agreement with Merck
    • 8.3.5. ECR Pharmaceuticals Enters into License Agreement with NovaDel Pharma
    • 8.3.6. Vanda Enters into Licensing Agreement with Bristol-Myers Squibb
  • 8.4. Co-Development Strategies

9. Sleep Disorders Market: Appendix

  • 9.1. Market Definition
  • 9.2. Abbreviations
  • 9.3. Research Methodology
    • 9.3.1. Coverage
    • 9.3.2. Secondary Research
    • 9.3.3. Forecasting
    • 9.3.4. Primary Research
    • 9.3.5. Expert Panels
  • 9.4. Contact Us
  • 9.5. Disclaimer
  • 9.6. Sources

List of Tables

  • Table 1: Sleep Disorders Market, Global, Revenue ($bn), 2002-2010
  • Table 2: Sleep Disorders Market, Global, Revenue Forecasts ($bn), 2010-2017
  • Table 3: Sleep Disorders Market, Global, Annual Cost of Treatment ($), 2002-2010
  • Table 4: Sleep Disorders Market, Global, Annual Cost of Treatment ($), 2010-2017
  • Table 5: Sleep Disorders Market, Global, Treatment Usage Patterns (millions), 2002-2010
  • Table 6: Sleep Disorders Market, Global, Treatment Usage Patterns (millions), 2010-2017
  • Table 7: Sleep Disorders Market, Global, Diseased Population (millions), 2002-2010
  • Table 8: Sleep Dis orders Market, Global, Diseased Population (millions), 2010-2017
  • Table 9: Sleep Disorders Market, Global, Treatment Seeking Population (millions), 2002-2010
  • Table 10: Sleep Disorders Market, Global, Treatment Seeking Population (millions), 2010-2017
  • Table 11: Sleep Disorders Market, Global, Diagnosed Population (million), 2002-2010
  • Table 12: Sleep Disorders Market, Global, Diagnosed Population (million), 2010-2017
  • Table 13: Sleep Disorders Market, Global, Prescription Population (million), 2002-2010
  • Table 14: Sleep Disorders Market, Global, Prescription Population (million), 2010-2017
  • Table 15: Sleep Disorders Market, Global, Revenue Analysis by Geography ($bn), 2002-2010
  • Table 16: Sleep Disorders Market, Global, Revenue Analysis by Geography ($bn), 2010-2017
  • Table 17: Sleep Disorders Market, the US, Revenue ($bn), 2002-2010
  • Table 18: Sleep Disorders Market, the US, Revenue Forecasts ($bn), 2010-2017
  • Table 19: Sleep Disorders Market, the US, Annual Cost of Treatment ($), 2002-2010
  • Table 20: Sleep Disorders Market, the US, Annual Cost of Treatment ($), 2010-2017
  • Table 21: Sleep Disorders Market, the US, Treatment Usage Patterns (millions), 2002-2010
  • Table 22: Sleep Disorders Market, the US, Treatment Usage Patterns (millions), 2010-2017
  • Table 23: Sleep Disorders Market, the US, Diseased Population (millions), 2002-2010
  • Table 24: Sleep Disorders Market, the US, Diseased Population (millions), 2010-2017
  • Table 25: Sleep Disorders Market, the US, Treatment Seeking Population (millions), 2002-2010
  • Table 26: Sleep Disorders Market, the US, Treatment Seeking Population (millions), 2010-2017
  • Table 27: Sleep Disorders Market, the US, Diagnosed Population (millions), 2002-2010
  • Table 28: Sleep Disorders Market, the US, Diagnosed Population (millions), 2010-2017
  • Table 29: Sleep Disorders Market, the US, Prescription Population (millions), 2002-2010
  • Table 30: Sleep Disorders Market, the US, Prescription Population (millions), 2010-2017
  • Table 31: Sleep Disorders Market, Top Five EU Countries, Revenue ($bn), 2002-2010
  • Table 32: Sleep Disorders Market, Top Five EU Countries, Revenue Forecasts ($bn), 2010-2017
  • Table 33: Sleep Disorders Market, Top Five Countries in the EU, Annual Cost of Treatment ($), 2002-2010
  • Table 34: Sleep Disorders Market, Top Five Countries in the EU, Annual Cost of Treatment ($), 2010-2017
  • Table 35: Sleep Disorders Market, Top Five Countries in the EU, Treatment Usage Patterns (millions), 2002-2010
  • Table 36: Sleep Disorders Market, Top Five Countries in the EU, Treatment Usage Patterns (millions), 2010-2017
  • Table 37: Sleep Disorders Market, Top Five Countries in Europe, Diseased Population (millions), 2002-2010
  • Table 38: Sleep Disorders Market, Top Five Countries in Europe, Diseased Population (millions), 2010-2017
  • Table 39: Sleep Disorders Market, Top Five Countries in Europe, Treatment Seeking Population (millions), 2002-2010
  • Table 40: Sleep Disorders Market, Top Five Countries in Europe, Treatment Seeking Population (millions), 2010-2017
  • Table 41: Sleep Disorders Market, Top Five Countries in Europe, Diagnosed Population (millions), 2002-2010
  • Table 42: Sleep Disorders Market, Top Five Countries in Europe, Diagnosed Population (millions), 2010-2017
  • Table 43: Sleep Disorders Market, Top Five Countries in Europe, Prescription Population (millions), 2002-2010
  • Table 44: Sleep Disorders Market, Top Five Countries in Europe, Prescription Population (millions), 2010-2017
  • Table 45: Sleep Disorders Market, Japan, Revenue ($bn), 2002-2010
  • Table 46: Sleep Disorders Market, Japan, Revenue Forecast ($bn), 2010-2017
  • Table 47: Sleep Disorders Market, Japan, Annual Cost of Treatment ($), 2002-2010
  • Table 48: Sleep Disorders Market, Japan, Annual Cost of Treatment ($), 2010-2017
  • Table 49: Sleep Disorders Market, Japan, Treatment Usage Patterns (millions), 2002-2010
  • Table 50: Sleep Disorders Market, Japan, Treatment Usage Patterns (millions), 2010-2017
  • Table 51: Sleep Disorders Market, Japan, Diseased Population (millions), 2002-2010
  • Table 52: Sleep Disorders Market, Japan, Diseased Population (millions), 2010-2017
  • Table 53: Sleep Disorders Market, Japan, Treatment Seeking Population (millions), 2002-2010
  • Table 54: Sleep Disorders Market, Japan, Treatment Seeking Population (millions), 2010-2017
  • Table 55: Sleep Disorders Market, Japan, Diagnosed Population (millions), 2002-2010
  • Table 56: Sleep Disorders Market, Japan, Diagnosed Population (millions), 2010-2017
  • Table 57: Sleep Disorders Market, Japan, Prescription Population (millions), 2002-2010
  • Table 58: Sleep Disorders Market, Japan, Prescription Population (millions), 2010-2017
  • Table 59: Insomnia Therapeutics Market, Global, Revenue ($bn), 2002-2010
  • Table 60: Insomnia Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017
  • Table 61: Insomnia Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
  • Table 62: Insomnia Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
  • Table 63: Insomnia Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010
  • Table 64: Insomnia Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2017
  • Table 65: Insomnia Therapeutics Market, Global, Diseased Population (millions), 2002-2010
  • Table 66: Insomnia Therapeutics Market, Global, Diseased Population (millions), 2010-2017
  • Table 67: Insomnia Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2010
  • Table 68: Insomnia Therapeutics Market, Global, Treatment Seeking Population (millions), 2010-2017
  • Table 69: Insomnia Therapeutics Market, Global, Diagnosed Population (millions), 2002-2010
  • Table 70: Insomnia Therapeutics Market, Global, Diagnosed Population (millions), 2010-2017
  • Table 71: Insomnia Therapeutics Market, Global, Prescription Population (millions), 2002-2010
  • Table 72: Insomnia Therapeutics Market, Global, Prescription Population (millions), 2010-2017
  • Table 73: Restless Leg Syndrome Therapeutics Market, Global, Revenue ($bn), 2002-2010
  • Table 74: Restless Leg Syndrome Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017
  • Table 75: Restless Leg Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
  • Table 76: Restless Leg Syndrome Therapeutics Market, Global, Annual Cost of Treatment($), 2010-2017
  • Table 77: Restless Leg Syndrome Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010
  • Table 78: Restless Leg Syndrome Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2017
  • Table 79: Restless Leg Syndrome Therapeutics Market, Global, Diseased Population (millions), 2002-2010
  • Table 80: Restless Leg Syndrome Therapeutics Market, Global, Diseased Population (millions), 2010-2017
  • Table 81: Restless Leg Syndrome Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2010
  • Table 82: Restless Leg Syndrome Therapeutics Market, Global, Treatment Seeking Population (millions), 2010-2017
  • Table 83: Restless Leg Syndrome Therapeutics Market, Global, Diagnosed Population (millions), 2002-2010
  • Table 84: Restless Leg Syndrome Therapeutics Market, Global, Diagnosed Population (millions), 2010-2017
  • Table 85: Restless Leg Syndrome Therapeutics Market, Global, Prescription Population (millions), 2002-2010
  • Table 86: Restless Leg Syndrome Therapeutics Market, Global, Prescription Population (millions), 2010-2017
  • Table 87: Narcolepsy Therapeutics Market, Global, Revenue ($m), 2002-2010
  • Table 88: Narcolepsy Therapeutics Market, Global, Revenue Forecast ($m), 2010-2017
  • Table 89: Narcolepsy Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
  • Table 90: Narcolepsy Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
  • Table 91: Narcolepsy Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002-2010
  • Table 92: Narcolepsy Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2010-2017
  • Table 93: Narcolepsy Therapeutics Market, Global, Diseased Population (thoousands), 2002-2010
  • Table 94: Narcolepsy Therapeutics Market, Global, Diseased Population (thoousands), 2010-2017
  • Table 95: Narcolepsy Therapeutics Market, Global, Treatment Seeking Population (thousands), 2002-2010
  • Table 96: Narcolepsy Therapeutics Market, Global, Treatment Seeking Population (thousands), 2010-2017
  • Table 97: Narcolepsy Therapeutics Market, Global, Diagnosed Population (thousands), 2002-2010
  • Table 98: Narcolepsy Therapeutics Market, Global, Diagnosed Population (thousands), 2010-2017
  • Table 99: Narcolepsy Therapeutics Market, Global, Prescription Population (thousands), 2002-2010
  • Table 100: Narcolepsy Therapeutics Market, Global, Prescription Population (thousands), 2010-2017
  • Table 101: Sleep Apnea Therapeutics Market, Global, Revenue ($m), 2002-2010
  • Table 102: Sleep Apnea Therapeutics Market, Global, Revenue Forecast ($m), 2010-2017
  • Table 103: Sleep Apnea Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
  • Table 104: Sleep Apnea Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
  • Table 105: Sleep Apnea Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010
  • Table 106: Sleep Apnea Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2017
  • Table 107: Sleep Apnea Therapeutics Market, Global, Prescription Population (millions), 2002-2010
  • Table 108: Sleep Apnea Therapeutics Market, Global, Diseased Population (millions), 2010-2017
  • Table 109: Sleep Apnea Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2010
  • Table 110: Sleep Apnea Therapeutics Market, Global, Treatment Seeking Population (millions), 2010-2017
  • Table 111: Sleep Apnea Therapeutics Market, Global, Diagnosed Population (millions), 2002-2010
  • Table 112: Sleep Apnea Therapeutics Market, Global, Diagnosed Population (millions), 2010-2017
  • Table 113: Sleep Apnea Therapeutics Market, Global, Prescription Population (millions), 2002-2010
  • Table 114: Sleep Apnea Therapeutics Market, Global, Prescription Population (millions), 2010-2017
  • Table 115: Insomnia Therapeutics Market, Global, Pipeline Analysis, NDA Filed Molecules
  • Table 116: Insomnia Therapeutics Market, Global, Pipeline Analysis, Phase III
  • Table 117: Insomnia Therapeutics Market, Global, Pipeline Analysis, Phase II
  • Table 118: Insomnia Therapeutics Market, Global, Pipeline Analysis, Phase I
  • Table 119: Insomnia Therapeutics Market, Global, Pipeline Analysis, Preclinical Phase
  • Table 120: Insomnia Therapeutics Market, Global, Pipeline Analysis, Discovery Phase
  • Table 121: Restless Leg Syndrome Therapeutics Market, Global, Pipeline Analysis
  • Table 122: Narcolepsy Therapeutics Market, Global, Pipeline Analysis
  • Table 123: Restless Leg Syndrome Therapeutics Market, Global, Pipeline Analysis
  • Table 124: Sleep Disorders Market, Global, Major M&A Deals, 2004-2010

List of Figures

  • Figure 1: Sleep Disorders Market, Global, Revenue Forecasts ($bn), 2002-2017
  • Figure 2: Sleep Disorders Market, Annual Cost of Treatment ($), 2002-2017
  • Figure 3: Sleep Disorders Market, Global, Treatment Usage Patterns (millions), 2002-2017
  • Figure 4: Sleep Disorders Market, Global, Diseased Population (millions), 2002-2017
  • Figure 5: Sleep Disorders Market, Global, Treatment Seeking Population (millions), 2002-2017
  • Figure 6: Sleep Disorders Market, Global, Diagnosis Population (million), 2002-2017
  • Figure 7: Sleep Disorders Market, Global, Prescription Population (million), 2002-2017
  • Figure 8: Sleep Disorders Market, Global, Revenue Analysis by Geography ($m), 2002-2017
  • Figure 9: Sleep Disorders Market, the US, Revenue Forecasts ($bn), 2002-2017
  • Figure 10: Sleep Disorders Market, the US, Annual Cost of Treatment ($), 2002-2017
  • Figure 11: Sleep Disorders Market, the US, Treatment Usage Patterns (millions), 2002-2017
  • Figure 12: Sleep Disorders Market, the US, Diseased Population (millions), 2002-2017
  • Figure 13: Sleep Disorders Market, the US, Treatment Seeking Population (millions), 2002-2017
  • Figure 14: Sleep Disorders Market, the US, Diagnosis Population (millions), 2002-2017
  • Figure 15: Sleep Disorders Market, the US, Prescription Population (millions), 2002-2017
  • Figure 16: Sleep Disorders Market, Top Five EU Countries, Revenue Forecasts ($bn), 2002-2017
  • Figure 17: Sleep Disorders Market, Top Five Countries in the EU, Annual Cost of Treatment ($), 2002-2017
  • Figure 18: Sleep Disorders Market, Top Five Countries in the EU, Treatment Usage Patterns (millions), 2002-2017
  • Figure 19: Sleep Disorders Market, Top Five Countries in the EU, Diseased Population (millions), 2002-2017
  • Figure 20: Sleep Disorders Market, Top Five Countries in the EU, Treatment Seeking Population (millions), 2002-2017
  • Figure 21: Sleep Disorders Market, Top Five Countries in the EU, Diagnosis Population (millions), 2002-2017
  • Figure 22: Sleep Disorders Market, Top Five Countries in the EU, Prescription Population (millions), 2002-2017
  • Figure 23: Sleep Disorders Market, Japan, Revenue Forecast ($bn), 2002-2017
  • Figure 24: Sleep Disorders Market, Japan, Annual Cost of Treatment ($), 2002-2017
  • Figure 25: Sleep Disorders Market, Japan, Treatment Usage Patterns (millions), 2002-2017
  • Figure 26: Sleep Disorders Market, Japan, Diseased Population (millions), 2002-2017
  • Figure 27: Sleep Disorders Market, Japan, Treatment Seeking Population (millions), 2002-2017
  • Figure 28: Sleep Disorders Market, Japan, Diagnosis Population (millions), 2002-2017
  • Figure 29: Sleep Disorders Market, Japan, Prescription Population (millions), 2002-2017
  • Figure 30: Insomnia Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017
  • Figure 31: Insomnia Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
  • Figure 32: Insomnia Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2017
  • Figure 33: Insomnia Therapeutics Market, Global, Diseased Population (millions), 2002-2017
  • Figure 34: Insomnia Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2017
  • Figure 35: Insomnia Therapeutics Market, Global, Diagnosis Population (millions), 2002-2017
  • Figure 36: Insomnia Therapeutics Market, Global, Prescription Population (millions), 2002-2017
  • Figure 37: Insomnia Therapeutics Market, Global, Market Drivers and Barriers, 2010-2017
  • Figure 38: Restless Leg Syndrome Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017
  • Figure 39: Restless Leg Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
  • Figure 40: Restless Leg Syndrome Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2017
  • Figure 41: Restless Leg Syndrome Therapeutics Market, Global, Diseased Population (millions), 2002-2017
  • Figure 42: Restless Leg Syndrome Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2017
  • Figure 43: Restless Leg Syndrome Therapeutics Market, Global, Diagnosis Population (millions), 2002-2017
  • Figure 44: Restless Leg Syndrome Therapeutics Market, Global, Prescription Population (millions), 2002-2017
  • Figure 45: Restless Leg Syndrome, Therapeutics Market, Drivers and Barriers, 2010-2017
  • Figure 46: Narcolepsy Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017
  • Figure 47: Narcolepsy Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
  • Figure 48: Narcolepsy Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002-2017
  • Figure 49: Narcolepsy Therapeutics Market, Global, Diseased Population (thousands), 2002-2017
  • Figure 50: Narcolepsy Therapeutics Market, Global, Treatment Seeking Population (thousands), 2002-2017
  • Figure 51: Narcolepsy Therapeutics Market, Global, Diagnosis Population (thousands), 2002-2017
  • Figure 52: Narcolepsy Therapeutics Market, Global, Prescription Population (thousands), 2002-2017
  • Figure 53: Narcolepsy Therapeutics Market, Global, Drivers and Barriers, 2010-2017
  • Figure 54: Sleep Apnea Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017
  • Figure 55: Sleep Apnea Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
  • Figure 56: Sleep Apnea Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2017
  • Figure 57: Sleep Apnea Therapeutics Market, Global, Diseased Population (millions), 2002-2017
  • Figure 58: Sleep Apnea Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2017
  • Figure 59: Sleep Apnea Therapeutics Market, Global, Diagnosed Population (millions), 2002-2017
  • Figure 60: Sleep Apnea Therapeutics Market, Global, Prescription Population (millions), 2002-2017
  • Figure 61: Sleep Apnea Therapeutics, Market Drivers and Barriers, 2010-2017
  • Figure 62: Sleep Disorders Market, Global, R&D Pipeline by Indications (%), 2010
  • Figure 63: Sleep Disorders Market, Global, R&D Pipeline by Phase (%), 2010
  • Figure 64: Insomnia Therapeutics Market, Global, Pipeline by Phase and Class, 2010
  • Figure 65: Restless Leg Syndrome Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010
  • Figure 66: Narcolepsy Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010
  • Figure 67: Sleep Apnea Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010
  • Figure 68: SWOT Analysis of Sanofi-Aventis
  • Figure 69: SWOT Analysis of King Pharmaceuticals, Inc.
  • Figure 70: SWOT Analysis of Questcor Pharmaceuticals
  • Figure 71: SWOT Analysis of Novartis
  • Figure 72: SWOT Analysis of GlaxoSmithKline
  • Figure 73: SWOT Analysis of Pfizer
  • Figure 74: SWOT Analysis of Boehringer Ingelheim GmbH
  • Figure 75: SWOT Analysis of Cephalon Pharmaceuticals
  • Figure 76: SWOT Analysis of Schwarz Pharma
  • Figure 77: SWOT Analysis of Mylan Pharma
  • Figure 78: Sleep Disorders Market, Global, Deals by Type, 2004-2010
  • Figure 79: Sleep Disorders Market, Global, Major Deals By Year, 2008-2010
  • Figure 80: Sleep Disorder Market, Global, Major Deals By Geography, 2004-2010
  • Figure 81: Sleep Disorder Market, Global, Co-Development Strategies By Geography, 2004-2010
  • Figure 82: GBI Research Market Forecasting Model
Back to Top